

Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 17:27:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 119 TO ITERATE
```

100.0% PROCESSED	119 ITERATIONS	1 ANSWERS
SEARCH TIME:	00.00.01	

FULL FILE PROJECTIONS:	ONLINE **COMPLETE**
	BATCH **COMPLETE**
PROJECTED ITERATIONS:	1726 TO 3034
PROJECTED ANSWERS:	1 TO 80

L2 1 SEA SSS SAM L1

```
=> s 11 sss full
FULL SEARCH INITIATED 17:27:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2285 TO ITERATE
```

100.0% PROCESSED	2285 ITERATIONS	42 ANSWERS
SEARCH TIME:	00.00.01	

L3 42 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 17:27:24 ON 10 APR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

09/888840

Page 4

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15  
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s 13  
L4                6 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002-717059 CAPLUS  
 DOCUMENT NUMBER: 137:247710  
 TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
 INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
 PATENT ASSIGNEE(S): USPTO  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.  
 CODEN: USXCC0  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPLN. INFO.:			US 2000-214983 P	P 20000629
OTHER SOURCE(S):		MARPAT 137:247710		

GI




AB The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prep'd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20

.mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4-(1-P(F3C)C6H3CO)Me, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.


IT 388117-63-3P 388117-64-4P 388117-65-5P  
 388117-66-6P 388117-67-7P 388117-68-8P  
 388117-69-9P 388117-70-2P 388117-71-3P  
 388117-72-4P 388117-73-5P 388117-74-6P  
 388117-75-7P 388117-76-8P 388117-77-9P  
 388117-78-0P 388117-79-1P 388117-80-4P  
 388117-81-5P 388117-82-6P 388117-83-7P  
 388117-84-8P 388117-85-9P 388117-86-0P  
 388117-87-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 antiinflammatory and immunosuppressive agents)  
 RN 388117-63-3 CAPLUS  
 CN Morpholine, 4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS  
 CN 4-Piperidinol, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-65-5 CAPLUS  
 CN Morpholine, 2,6-dimethyl-4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-66-6 CAPLUS  
 CN 3-Piperidinecarboxamide, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-67-7 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-68-8 CAPLUS  
 CN Acetamide, N-ethyl-N-[1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-70-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-71-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-73-5 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388117-74-6 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-75-7 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-76-0 CAPLUS  
 CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-6-(4-(2-pyridinyl)-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 388117-77-9 CAPLUS  
 CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-78-0 CAPLUS  
 CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-6-(3-(1H-tetrazol-5-yl)-1-piperidinyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 388117-79-1 CAPLUS  
 CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-6-(4-(1H-tetrazol-5-yl)-1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 388117-80-4 CAPLUS  
 CN 3-Piperidinemethanol, 1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-81-5 CAPLUS  
 CN 4-Piperidineethanol, 1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
 CN Acetamide, N-[1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS  
 CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 388117-84-8 CAPLUS  
 CN 3-Pyrrolidinol, 1-[6-[4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-85-9 CAPLUS  
 CN Carbamic acid, [1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 388117-86-0 CAPLUS  
 CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS  
 CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)




IT 388118-57-8P 388118-58-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)  
 RN 388118-57-8 CAPLUS  
 CN 4(1H)-Pyrimidinone, 6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS  
 CN Pyrimidine, 4-chloro-6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:449662 CAPLUS  
 DOCUMENT NUMBER: 137:33310  
 TITLE: Preparation of anilinopyrimidines as IKK inhibitors  
 INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shirish S.; Parnes, Jason S.; Palanki, Dorothy S. S.; Erdman, Paul E.  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int Appl., 194 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, CY, DE, DK, ES, FI, FR, GB, GR, IS, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		
	RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IS, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG		
AU 2002020195	A5	20020618	AU 2002-20195	20011205
			US 2000-251816P	P 20001206
			WO 2001-US46403	W 20011205

OTHER SOURCE(S): MARPAT 137:33310  
 GI



AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)bCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepnd. E.g., a multi-step synthesis of I [R1 = 4-OCH3H4; R2-R6 = H] having an IC50 of 1.10eq. 1 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.

IT 434944-80-8P 434945-04-7P 434945-05-8P  
 434945-27-4P 434950-45-5P 434950-46-6P

## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


434950-47-7P 434950-48-8P 434950-49-9P  
 434950-50-2P 434950-51-3P 434950-52-4P  
 434950-53-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of anilinopyrimidines as IKK inhibitor)

RN 434944-90-8 CAPLUS


CN Benzamide,

4-[(4-[4-(4-chlorophenyl)sulfonyl]phenyl)-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)




RN 434945-04-7 CAPLUS

CN Benzamide, 4-[(4-[4-(phenylthio)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 434945-05-8 CAPLUS

CN Benzamide, 4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS

CN Morpholine, 4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)

## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


434950-45-5 CAPLUS

Piperazine, 1-(2-ethoxyethyl)-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-46-6 CAPLUS

CN Piperazine, 1-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]-4-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS


CN Piperazine, 1-acetyl-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)



## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434950-48-8 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-49-9 CAPLUS

CN Piperazine, 1-methyl-1-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-50-2 CAPLUS

CN Piperazine, 1-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)



• 2 HCl


RN 434950-51-3 CAPLUS

CN 1-Piperazinepropanamine, N,N-dimethyl-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)

## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


434950-52-4 CAPLUS

Benzamide, N-(4-hydroxycyclohexyl)-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)



RN 434950-52-5 CAPLUS

CN Benzamide, N,N-dimethyl-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:449661 CAPLUS  
 DOCUMENT NUMBER: 137:33309  
 TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors  
 INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satch, Yoshitaka;  
 Bhagwat, Shripad S.; Parnes, Jason S.; Palanki,  
 Moorthy S. S.; Erdman, Paul E.  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 199 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 2002027214	AS	20020618	AU 2002-27214	20011205
PRIORITY APPLN. INFO.:			US 2000-251904P	P 20001206
			WO 2001-US46402	W 20011205


OTHER SOURCE(S): MARPAT 137:33309

GI




AB The title compd. [I]; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prep'd. E.g., a multi-step synthesis of I [R1 = 4-C1C6H4; R2-R6 = H] having an IC50 of .1toreq. 10  $\mu$ M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compsns.


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-45-5 CAPLUS  
 CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS  
 CN Piperazine, 1-[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-[tetrahydro-2-furanyl]methyl]- (9CI) (CA INDEX NAME)



RN 434950-47-7 CAPLUS  
 CN Piperazine, 1-acetyl-4-[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-48-8 CAPLUS

Habte


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 contg. one or more compds. of the above compds.

IT 434944-90-8P 434945-04-7P 434945-05-8P  
 434945-27-4P 434950-45-5P 434950-46-6P  
 434950-47-7P 434950-48-8P 434950-49-9P  
 434950-50-2P 434950-51-3P 434950-52-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of anilinopyrimidines as JNK pathway inhibitor)


RN 434944-90-8 CAPLUS  
 CN Benzamide,  
 4-[(4-chlorophenyl)sulfonyl]phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS  
 CN Benzamide, 4-[(4-phenylthio)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)




RN 434945-05-8 CAPLUS  
 CN Benzamide, 4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino]- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS  
 CN Morpholine, 4-[(4-phenylsulfonyl)phenyl]-2-


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-49-9 CAPLUS  
 CN Piperazine, 1-methyl-4-[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-50-2 CAPLUS  
 CN Piperazine, 1-[4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]- dihydrochloride (9CI) (CA INDEX NAME)




• 2 HCl

RN 434950-51-3 CAPLUS  
 CN 1-Piperazinepropanamine,  
 N,N-dimethyl-4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-52-4 CAPLUS  
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 434950-53-5 CAPLUS  
CN Benzamide, N,N-dimethyl-4-[(4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002:31429 CAPLUS  
DOCUMENT NUMBER: 136:102394  
TITLE: Aryl phenylheterocycl sulfides derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
PATENT ASSIGNEE(S): Abbott Lab., USA  
SOURCE: PCT Int. Appl., 135 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1294704	A1	20030326	EP 2001-946705	20010622
R: AT, BE, CH, DE, DK, ES, PR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		R: US 2000-606717	A 20000629	
PRIORITY APPLN. INFO.:		WO 2001-US20128	W 20010622	
OTHER SOURCE(S): G1		MARPAT 136:102394		




AB Title compds. were prep'd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC50 <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHG6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.  
IT 388118-57-8P 388118-58-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(prepns. of aryl phenylheterocycl sulfides as cell adhesion-inhibiting anti-inflammatory and immunosuppressive agents)

RN 388118-57-8 CAPLUS  
CN 4-(1H)-Pyrimidinone, 6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 388118-58-9 CAPLUS  
CN Pyrimidine, 4-chloro-6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




IT 388117-63-3P 388117-64-4P 388117-65-5P  
388117-66-6P 388117-67-7P 388117-68-8P  
388117-69-9P 388117-70-3P 388117-73-3P  
388117-73-4P 388117-73-5P 388117-74-6P  
388117-75-7P 388117-76-8P 388117-77-9P  
388117-78-0P 388117-79-1P 388117-80-4P  
388117-81-5P 388117-82-6P 388117-83-7P  
388117-84-8P 388117-85-9P 388117-86-0P  
388117-87-1P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepns. of aryl phenylheterocycl sulfides as cell adhesion-inhibiting anti-inflammatory and immunosuppressive agents)


RN 388117-63-3 CAPLUS  
CN Morpholine, 4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 388117-64-4 CAPLUS  
CN 4-Piperidinol, 1-[(2-(1-methylethyl)phenyl]thio)-3-

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)


RN 388117-65-5 CAPLUS  
CN Morpholine, 2,6-dimethyl-4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



RN 388117-66-6 CAPLUS  
CN 3-Piperidinecarboxamide, 1-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)




RN 388117-67-7 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 388117-68-8 CAPLUS

CN Acetamide, N-ethyl-N-[1-(6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-70-2 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-74-6 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-76-8 CAPLUS

CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-6-[4-(2-pyridinyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 388117-71-3 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-72-4 CAPLUS


CN 1-Piperazineacetic acid, 4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 388117-73-5 CAPLUS


CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-77-9 CAPLUS

CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-78-0 CAPLUS

CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 388117-79-1 CAPLUS


CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 RN 388117-80-4 CAPLUS  
 CN 3-Piperidinemethanol, 1-[6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-81-5 CAPLUS  
 CN 4-Piperidineethanol, 1-[6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
 CN Acetamide, N-[1-[6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 388117-83-7 CAPLUS  
 CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 Absolute stereochemistry.




RN 388117-84-8 CAPLUS  
 CN 3-Pyrrolidinol, 1-[6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, (3R)- (9CI) (CA INDEX NAME)  
 Absolute stereochemistry.




RN 388117-85-9 CAPLUS  
 CN Carboxylic acid, [1-[6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, 1,1-dimethyl-ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-86-0 CAPLUS  
 CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388117-87-1 CAPLUS  
 CN 4-Pyrimidinamine,  
 N-ethyl-N-methyl-6-{4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1992-612432 CAPLUS  
 DOCUMENT NUMBER: 117:212432  
 TITLE: Studies on cerebral protective agents. I. Novel 4-arylpurimidines derivatives with anti-anoxic and anti-lipid peroxidation activities  
 AUTHOR(S): Kuno, Atsushi; Sugiyama, Yoshie; Katauta, Kiyotaka; Kamitani, Toshiharu; Takasugi, Hisashi  
 CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan  
 SOURCE: Chemical & Pharmaceutical Bulletin (1992), 40(6), 1452-61  
 DOCUMENT TYPE: CODEN: CPBTAL; ISSN: 0009-2363  
 LANGUAGE: English  
 GI



AB Novel 4-arylpurimidin derivs. were synthesized by the oxidn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds., Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl)

has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-O2NC6H4) has ALP activity (73% inhibition at 10-5 g/ml). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of Vitamin E.

IT 103293-67-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn., anti-anoxic and anti-lipid peroxidn. activities of)  
 RN 103293-67-0 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid,  
 4-(2-[(4-chlorophenyl)thiophenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1986:572492 CAPLUS  
 DOCUMENT NUMBER: 105:172492  
 TITLE: Pyrimidine derivatives  
 INVENTOR(S): Takaya, Takao; Takesugi, Hisashi; Kuno, Atsushi;  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 192 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 169712	A2	19860129	EP 1985-305143	19850718
EP 169712	A3	19861203		
EP 169712	B1	19901212		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4698340	A	19871006	US 1985-753912	19850711
ZA 8505369	A	19860625	ZA 1985-5369	19850716
PI 8502796	A	19860120	PI 1985-2796	19850717
NO 8502869	A	19860120	NO 1985-2869	19850718
DK 8503279	A	19860120	DK 1985-3279	19850718
ES 545347	A1	19861016	ES 1985-545347	19850718
AT 59034	E	19901215	AT 1985-305143	19850718
AU 8545202	A1	19860123	AU 1985-45202	19850719
JP 61040272	A2	19860226	JP 1985-160784	19850719
JP 06049688	B4	19940629		
US 4727073	A	19880223	US 1985-779043	19850923
ZA 8507359	A	19860528	ZA 1985-7359	19850924
PI 8503698	A	19860402	PI 1985-3698	19850926
EP 172287	A2	19860409	EP 1985-306880	19850927
EP 172287	A3	19861126		
EP 172287	B1	19901205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 58897	E	19901215	AT 1985-306880	19850927
DK 8504436	A	19860402	DK 1985-4436	19850930
NO 8503853	A	19860402	NO 1985-3853	19850930
ES 547419	A1	19870316	ES 1985-547419	19850930
AU 8548143	A1	19860410	AU 1985-48143	19851001
JP 61087669	A2	19860506	JP 1985-219010	19851001
PRIORITY APPLN. INFO.:				
			GB 1984-18380	19840719
			GB 1984-24711	19841001
			GB 1985-9623	19850415
			GB 1985-9633	19850415
			EP 1985-305143	19850718
			EP 1985-306880	19850927

GI

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Pyrimidines I (R = substituted aryl; R1 = CO2H, esterified CO2H, alkancoyl,  
 etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prep'd., and they  
 showed their usefulness in the treatment of cerebrovascular diseases.

Dihydropyrimidine deriv. II was heated with MnO2 to give I (R = 4-pyridyl,


R1 = CO2Et, R2 = Me, R3 = Ph). II was prep'd. from an alpha-(arylmethylene)acetooacetate ester and an amidine.

IT 103293-67-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prep'n of, for treatment of cerebrovascular disease)

RN 103293-67-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid,  
 4-[2-[(4-chlorophenyl)chlorophenyl]-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



09/888840

Page 14

=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	27.63	175.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.91	-3.91

STN INTERNATIONAL LOGOFF AT 17:27:58 ON 10 APR 2003


Narrow  
search

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
 Uploading 09888840narrow.str

L1 STRUCTURE UPLOADED

=> d 11  
 L1 HAS NO ANSWERS  
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11  
 SAMPLE SEARCH INITIATED 10:17:53 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS 0 ANSWERS  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 3 TO 163  
 PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 sss full  
 FULL SEARCH INITIATED 10:18:02 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 31 TO ITERATE

100.0% PROCESSED 31 ITERATIONS 1 ANSWERS  
 SEARCH TIME: 00.00.01

L3 1 SEA SSS FUL L1

=> file caplus  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
                                   ENTRY SESSION

FULL ESTIMATED COST	148.15	148.36
---------------------	--------	--------

FILE 'CAPLUS' ENTERED AT 10:18:08 ON 08 APR 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2003 VOL 138 ISS 15  
 FILE LAST UPDATED: 7 Apr 2003 (20030407/ED)



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
 L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:717059 CAPLUS  
 DOCUMENT NUMBER: 137:247710  
 TITLE: Preparation of aryl phenylheterocycl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
 INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
US 2002132807	A1	20020919	US 2001-888840	20010625
PRIORITY APPLN. INFO.:			US 2000-214983P	P 20000629
OTHER SOURCE(S):		MARPAT 137:247710		
GI				



**AB** The title compds. [I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl] were prep'd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC50 <20 .mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me2CHC6H4SH was etherified with 4,3-F(F3C)C6H3COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.


**IT** 388117-75-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:31429 CAPLUS

DOCUMENT NUMBER: 136:102394

TITLE: Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents

INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert

PATENT ASSIGNEE(S): Abbott Lab., USA

SOURCE: PCT Int. Appl., 135 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,  
 VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


EP 1294704 A1 20030326 EP 2001-946705 20010622

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-606717 A 20000629  
 WO 2001-US20128 W 20010622

OTHER SOURCE(S): MARPAT 136:102394

GI




AB Title compds. were prep'd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC<sub>50</sub> <20 mM for inhibition of ICAM-1 binding to LFA-1. 2-Me<sub>2</sub>CHC<sub>6</sub>H<sub>4</sub>SH was etherified with 4,3-F(F<sub>3</sub>C)C<sub>6</sub>H<sub>3</sub>COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT 388117-75-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-75-7 CAPLUS

CN 3-Piperidinecarboxylic acid, 1-[6-[[4-[[2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log Y  
 COST IN U.S. DOLLARS

SINCE FILE TOTAL


09/888840

Page 7

FULL ESTIMATED COST	ENTRY 9.49	SESSION 157.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 10:18:32 ON 08 APR 2003

*Broad Search*



Structure attributes must be viewed using STN Express query preparation.

```
=> s 11
SAMPLE SEARCH INITIATED 17:33:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2803 TO ITERATE
```

```
35.7% PROCESSED    1000 ITERATIONS          0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH **COMPLETE**
PROJECTED ITERATIONS:      52886 TO      59234
PROJECTED ANSWERS:         0 TO         0
```

L2 0 SEA SSS SAM L1

```
=> s 11 sss full
FULL SEARCH INITIATED 17:33:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 55054 TO ITERATE
```

```
100.0% PROCESSED    55054 ITERATIONS        107 ANSWERS
SEARCH TIME: 00.00.02
```

L3 107 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	148.15	148.36

```
FILE 'CAPLUS' ENTERED AT 17:33:50 ON 10 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Apr 2003 VOL 138 ISS 15  
FILE LAST UPDATED: 9 Apr 2003 (20030409/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 13
L4           6 L3
```

```
=> d ibib abs histr tot
'HISTR' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATTS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
          SCAN must be entered on the same line as the DISPLAY,
          e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
            containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
            its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
            structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
```

its structure diagram

FHITSEQ ----- First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields

KWIC ----- Hit term plus 20 words on either side

OCC ----- Number of occurrence of hit term and field in which it occurs


To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:717059 CAPLUS  
 DOCUMENT NUMBER: 137:247710  
 TITLE: Preparation of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
 INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 44 pp.  
 CODEN: USXKCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:  
 PATENT NO. KIND DATE APPLICATION NO. DATE  
 US 2002132807 AI 20020919 US 2001-888840 20010625  
 PRIORITY APPLN. INFO.: US 2000-214983 P 20000629  
 OTHER SOURCE(S): MARPAT 137:247710  
 GI




AB The title compds. (I; R1-R5 = H, halo, alkyl, etc. (with proviso that at least one of R1 or R3 = (un)substituted pyridyl, pyrimidyl, oxazolyl, etc.); A = (un)substituted aryl, heterocyclyl) were prep'd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products I had IC<sub>50</sub> <20

.mu.M for inhibition of ICAM-1 binding to LFA-1. 2-Me<sub>2</sub>CHC<sub>6</sub>H<sub>4</sub>SH was etherified with 4,3-F(9CI)C<sub>6</sub>H<sub>3</sub>COMe, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide II.


IT 388117-63-3P 388117-64-4P 388117-65-5P  
 388117-66-6P 388117-67-7P 388117-68-8P  
 388117-69-9P 388117-70-2P 388117-71-3P  
 388117-72-4P 388117-73-5P 388117-74-6P  
 388117-75-7P 388117-76-8P 388117-77-9P  
 388117-78-0P 388117-79-1P 388117-80-4P  
 388117-81-5P 388117-82-6P 388117-83-7P  
 388117-84-8P 388117-85-9P 388117-86-0P  
 388117-87-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 antiinflammatory and immunosuppressive agents)  
 RN 388117-63-3 CAPLUS  
 CN Morpholine, 4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 388117-64-4 CAPLUS  
 CN 4-Piperidinol, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-65-5 CAPLUS  
 CN Morpholine, 2,6-dimethyl-4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-66-6 CAPLUS  
 CN 3-Piperidinecarboxamide, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-67-7 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 388117-68-8 CAPLUS  
 CN Acetamide, N-ethyl-N-[1-{6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl}-4-pyrimidinyl]-3-pyrrolidinyl- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-70-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-71-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-73-5 CAPLUS  
CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388117-74-6 CAPLUS  
CN 4-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-75-7 CAPLUS  
CN 3-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-76-8 CAPLUS  
CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 388117-77-9 CAPLUS  
CN 3-Piperidinecarboxamide, N,N-diethyl-1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-78-0 CAPLUS  
CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[3-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 388117-79-1 CAPLUS  
CN Pyrimidine, 4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-6-[4-(1H-tetrazol-5-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



RN 388117-80-4 CAPLUS  
CN 3-Piperidinemethanol, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-81-5 CAPLUS  
CN 4-Piperidineethanol, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-82-6 CAPLUS  
CN Acetamide, N-[1-[6-[4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-83-7 CAPLUS  
CN Pyrimidine, 4-[(2R)-2-(methoxymethyl)-1-pyrrolidinyl]-6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 388117-84-8 CAPLUS  
CN 3-Pyrrolidinol, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-85-9 CAPLUS  
CN Carbamic acid, [1-[6-[(4-[(2-(1-methylethyl)phenyl]thio)-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 388117-86-0 CAPLUS  
CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388118-57-1 CAPLUS  
CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 388118-57-0P 388118-58-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of aryl phenylheterocycl sulfides as cell adhesion-inhibiting, antiinflammatory and immunosuppressive agents)  
RN 388118-57-8 CAPLUS  
CN 4(1H)-Pyrimidone, 6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 388118-58-9 CAPLUS  
CN Pyrimidone, 4-chloro-6-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002-449662 CAPLUS  
DOCUMENT NUMBER: 137-33310  
TITLE: Preparation of anilincopyrimidines as IKK inhibitors  
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Sato, Yoshitaka;  
Bhagwat, Shripad S.; Parnes, Jason S.; Palanki,  
Moorthy S. S.; Erdman, Paul E.  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
SOURCE: PCT Int'l Appl., 194 pp.  
CODEN: PIXDZ2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZR, ZT, KG, KZ, MD, RU, TJ, TR, UA, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PI, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 200220195	A5	20020618	AU 2002-20195	20011205
PRIORITY APPLN. INFO.:			US 2000-251816P	P 20001206
			WO 2001-US46403	W 20011205

OTHER SOURCE(S): MARPAT 137:33310  
G1



AB The title compds. (I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)nCOR9, (CH2)nCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; n = 0-4) having activity as inhibitors of IKK, particularly IKK-2, were prep'd. E.g., a multi-step synthesis of I (R1 = 4-ClC6H4; R2-R6 = H) having an IC50 of 1.04 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.

IT 434944-90-0P 434944-91-9P 434944-92-0P  
434944-93-4P 434944-99-7P 634945-00-3P

4/8/2003

## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

434945-01-4P 434945-04-7P 434945-05-8P  
 434945-27-4P 434945-75-2P 434945-76-3P  
 434945-28-7P 434945-29-8P 434945-31-2P  
 434945-33-4P 434945-35-6P 434945-36-7P  
 434945-38-9P 434945-40-3P 434945-42-5P  
 434945-44-7P 434945-47-0P 434945-50-5P  
 434945-53-8P 434945-56-1P 434945-68-5P  
 434945-71-0P 434945-74-3P 434945-77-6P  
 434945-79-8P 434945-81-2P 434945-83-4P  
 434945-85-6P 434945-87-8P 434945-91-4P  
 434945-94-7P 434945-95-8P 434945-96-9P  
 434945-97-0P 434945-98-1P 434945-99-2P  
 434950-03-5P 434950-04-6P 434950-05-7P  
 434950-06-8P 434950-07-9P 434950-08-0P  
 434950-09-1P 434950-10-4P 434950-11-5P  
 434950-12-6P 434950-13-7P 434950-14-8P  
 434950-15-9P 434950-16-11P 434950-34-2P  
 434950-35-3P 434950-36-4P 434950-37-5P  
 434950-38-6P 434950-39-7P 434950-40-0P  
 434950-41-1P 434950-42-2P 434950-43-3P  
 434950-44-4P 434950-45-5P 434950-46-6P  
 434950-47-7P 434950-48-8P 434950-49-9P  
 434950-50-2P 434950-51-3P 434950-52-4P  
 434950-53-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilinopyrimidines as IKK inhibitors)

RN 434944-90-8 CAPLUS

CN Benzamide,


4-[(4-[(4-chlorophenyl)sulfonyl]phenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS


CN Benzamide, 4-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)

## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434944-92-0 CAPLUS

CN Benzamide, 4-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)




RN 434944-96-4 CAPLUS

CN Benzamide, 4-[(4-[(3-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)



RN 434944-99-7 CAPLUS

CN Benzamide, 4-[(4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434945-00-3 CAPLUS


## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Benzamide, 4-[(4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl)-2-pyrimidinyl]amino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434944-99-7

CMF C2 H25 N5 O3 S



CM 2


CRN 76-05-1

CMF C2 H25 N5 O2



RN 434945-01-4 CAPLUS


CN Benzamide, 4-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)



RN 434945-04-7 CAPLUS


CN Benzamide, 4-[(4-[(phenylthio)phenyl]-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)

## L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434945-05-8 CAPLUS

CN Benzamide, 4-[(4-[(phenylthio)phenyl]-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS

CN Morpholine, 4-[(4-[(phenylthio)phenyl]-2-pyrimidinyl]amino)benzoyl]- (9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS


CN Piperazine, 1-acetyl-4-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl)- (9CI) (CA INDEX NAME)




RN 434945-76-3 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-28-7 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-31-2 CAPLUS  
CN Piperazine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-33-4 CAPLUS  
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-40-3 CAPLUS  
CN 4-Piperidinol, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434949-42-5 CAPLUS  
CN Piperidine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Habte

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-35-6 CAPLUS  
CN Piperazine, 3-methyl-1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 434949-36-7 CAPLUS  
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-38-9 CAPLUS  
CN Piperazine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A

PAGE 1-A




RN 434949-44-7 CAPLUS  
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-47-0 CAPLUS  
CN Piperazine, 1-[2,2-dimethyl-1-oxopropyl]-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX)

4/8/2003


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-50-5 CAPLUS  
CN Piperazine, 1-[4-[(4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 434949-53-8 CAPLUS  
CN Piperazine, 1-[4-[(4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 434949-56-1 CAPLUS  
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[(4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




RN 434949-68-5 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[(4-[(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-71-0 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-[(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)- (9CI) (CA INDEX NAME)



RN 434949-74-3 CAPLUS  
CN Piperazine, 1-[4-[(4-[(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)- (9CI) (CA INDEX NAME)




RN 434949-77-6 CAPLUS  
CN Piperidine, 1-[4-[(4-[(4-hydroxy-1-piperidinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 434949-79-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-81-2 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-[(4-acetyl-1-piperazinyl)carbonyl]phenylamino)-4-pyrimidinylphenyl]sulfonyl)- (9CI) (CA INDEX NAME)



RN 434949-83-6 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[(4-[(4-acetyl-1-piperazinyl)carbonyl]phenylamino)-4-pyrimidinylphenyl]sulfonyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 434949-85-6 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-[(1-piperidinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)- (9CI) (CA INDEX NAME)




RN 434949-87-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-[(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinylamino]benzoyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-91-4 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-(1-pyrrolidinyl)-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-94-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-99-2 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-(1-piperazinylsulfonyl)phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS  
CN Piperazine, 1-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-04-6 CAPLUS  
CN Piperazine, 1-[4-[(4-(1-pyrrolidinylsulfonyl)phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-05-7 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-

Habte


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-95-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-97-0 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-98-1 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-[(3-hydroxy-1-piperidinyl)sulfonyl]phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
pyrimidinylamino]benzoyl]-, (3R,SS)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-06-8 CAPLUS  
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-07-9 CAPLUS  
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-08-0 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[4-[(4-(1-pyrrolidinylsulfonyl)phenyl)-2-pyrimidinylamino]benzoyl]-, (3R,SS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-09-1 CAPLUS  
 CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[(4-(1-pyrrolidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-10-4 CAPLUS  
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[[4-[(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-11-5 CAPLUS  
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[(4-[(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-12-6 CAPLUS  
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[(4-[(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-13-7 CAPLUS  
 CN Piperazine, 3,5-dimethyl-1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl - (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-14-8 CAPLUS  
 CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-15-9 CAPLUS  
 CN 1-Piperazineethanamine, N,N-dimethyl-4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-33-1 CAPLUS  
 CN 1-Piperazinepropanamine, N,N-dimethyl-4-[(4-[(4-tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-34-2 CAPLUS  
 CN 4-Piperidinol, 1-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-35-3 CAPLUS  
 CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 2-A




RN 434950-36-4 CAPLUS  
 CN Piperazine, 1-(2-furanylcarbonyl)-4-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS  
 CN 1-Piperazineacetamide, N-(1-methylethyl)-4-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)




RN 434950-38-6 CAPLUS  
 CN Piperazine, 1-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-39-7 CAPLUS  
 CN Piperazine, 3-methyl-1-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (3R) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434950-40-0 CAPLUS  
 CN Piperidine, 4-(1-pyrrolidinyl)-1-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)




RN 434950-41-1 CAPLUS  
 CN 4-Piperidinol, 1-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)




RN 434950-42-2 CAPLUS  
 CN Piperazine, 1-{[3,5-dimethyl-4-isoxazolyl]carbonyl}-4-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 434950-43-3 CAPLUS  
 CN Piperazine, 1-acetyl-4-{4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)




RN 434950-44-4 CAPLUS  
 CN Piperazine, 1-{4-[4-(4-pyridinylsulfonyl)phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS  
 CN Piperazine, 1-(2-ethoxyethyl)-4-{4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS  
 CN Piperazine, 1-{4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino}benzoyl-4-[(tetrahydro-2-furanyl)methyl] - (9CI) (CA INDEX NAME)




RN 434950-47-7 CAPLUS  
 CN Piperazine, 1-acetyl-4-{4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)




RN 434950-48-8 CAPLUS  
 CN Piperazine, 1-(2-furanylcarbonyl)-4-{4-[4-(phenylsulfonyl)phenyl]-2-pyrimidinylamino}benzoyl - (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-49-9 CAPLUS  
CN Piperazine, 1-methyl-4-[(4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-50-2 CAPLUS  
CN Piperazine, 1-[4-[(4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 434950-51-3 CAPLUS  
CN 1-Piperazinepropanamine,  
N,N-dimethyl-4-[(4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-52-4 CAPLUS  
CN Benzanide, N-[(4-hydroxycyclohexyl)-4-[(4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 434950-53-5 CAPLUS  
CN Benzanide, N,N-dimethyl-4-[(4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)



IT 434950-55-9P 434950-56-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepns. of anilinopyrimidines as IKK inhibitors)  
RN 434950-55-9 CAPLUS  
CN Benzoic acid,  
4-[(4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)




RN 434950-68-2 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN Benzoic acid, 4-[(4-((tetrahydro-2H-pyran-4-yl)sulfonyl)phenyl)-2-pyrimidinylamino)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 2002-449661 CAPLUS  
DOCUMENT NUMBER: 137-33309  
TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors  
INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy, S. C.; Erdman, Paul E.  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
SOURCE: PCT Int. Appl., 199 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001 US46402	20011205
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CZ, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU, ZA, ZB, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TA, TM, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG				
RW: GH, GM, KE, LS, MA, MZ, SD, SL, SZ, TZ, TW, ZA, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG				
AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRIORITY APPLN. INFO.:			US 2000-251904P	P 20001206
			WO 2001-US46402	W 20011205

OTHER SOURCE(S): MARPAT 137-33309  
GI

AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R6, (CH2)acOR9, (CH2)acOAR9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepnd. E.g., a multi-step synthesis of 1 [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of >10<sup>6</sup> M in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns.

contg. one or more compds. of the above compds.  
IT 434944-90-8P 434944-91-9P 434944-92-0P  
434944-96-4P 434944-99-7P 434945-00-3P

4/8/2003

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


434945-01-4P 434945-04-7P 434945-05-8P  
 434945-27-4P 434945-75-2P 434945-76-3P  
 434949-28-7P 434949-29-8P 434949-31-2P  
 434949-33-4P 434949-35-6P 434949-36-7P  
 434949-38-9P 434949-40-3P 434949-42-5P  
 434949-44-7P 434949-47-0P 434949-50-5P  
 434949-53-8P 434949-56-1P 434949-68-5P  
 434949-71-0P 434949-74-3P 434949-77-6P  
 434949-79-8P 434949-81-2P 434949-83-4P  
 434949-85-6P 434949-87-8P 434949-91-4P  
 434949-94-7P 434949-95-8P 434949-96-9P  
 434949-97-0P 434949-98-1P 434949-99-2P  
 434950-03-5P 434950-04-6P 434950-05-7P  
 434950-06-8P 434950-07-9P 434950-08-0P  
 434950-09-1P 434950-10-4P 434950-11-5P  
 434950-12-6P 434950-13-7P 434950-14-8P  
 434950-15-9P 434950-33-1P 434950-34-2P  
 434950-35-3P 434950-36-4P 434950-37-5P  
 434950-38-6P 434950-39-7P 434950-40-0P  
 434950-41-1P 434950-42-2P 434950-43-3P  
 434950-44-4P 434950-45-5P 434950-46-6P  
 434950-47-7P 434950-48-8P 434950-49-9P  
 434950-50-2P 434950-51-3P 434950-52-4P  
 434950-53-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of anilinopyrimidines as JNK pathway inhibitors)

RN 434944-90-8 CAPLUS


CN Benzamide, 4-[(4-(4-chlorophenyl)sulfonyl)phenyl]-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)



RN 434944-91-9 CAPLUS


CN Benzamide, 4-[(4-(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434944-92-0 CAPLUS

CN Benzamide, 4-[(4-(2-pyridinylsulfonyl)phenyl)-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)




RN 434944-96-4 CAPLUS

CN Benzamide, 4-[(4-(3-pyridinylsulfonyl)phenyl)-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)



RN 434944-99-7 CAPLUS

CN Benzamide, 4-[(4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl)-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)




RN 434945-00-3 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN Benzamide, 4-[(4-[(1-methyl-4-piperidinyl)sulfonyl]phenyl)-2-pyrimidinylamino], mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 434944-99-7

CHM C23 H25 N5 O3 S




CM 2

CRN 76-05-1

CHM C2 H F3 O2




RN 434945-01-4 CAPLUS  
 CN Benzamide, 4-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)




RN 434945-04-7 CAPLUS  
 CN Benzamide, 4-[(4-[4-(phenylthio)phenyl]-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434945-05-8 CAPLUS

CN Benzamide, 4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino]-(9CI) (CA INDEX NAME)




RN 434945-27-4 CAPLUS

CN Morpholine, 4-[(4-[(4-phenylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]-(9CI) (CA INDEX NAME)



RN 434945-75-2 CAPLUS


CN Piperazine, 1-acetyl-4-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]-(9CI) (CA INDEX NAME)




RN 434945-76-3 CAPLUS

CN Piperazine, 1-(2-furanylcarbonyl)-4-[(4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinylamino)benzoyl]-(9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-28-7 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434949-29-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-31-2 CAPLUS  
CN Piperazine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-33-4 CAPLUS  
CN 1-Piperazineacetamide, N-(1-methylethyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-35-6 CAPLUS  
CN Piperazine, 3-methyl-1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 434949-36-7 CAPLUS  
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-38-9 CAPLUS  
CN Piperazine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl-4-[2-oxo-2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



PAGE 1-A



PAGE 1-A




PAGE 2-A



PAGE 2-A


RN 434949-40-3 CAPLUS  
CN 4-Piperidinol, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434949-42-5 CAPLUS  
CN Piperidine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Habte


RN 434949-44-7 CAPLUS  
CN Piperazine, 1-(cyclopropylcarbonyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434949-47-0 CAPLUS  
CN Piperazine, 1-(2,2-dimethyl-1-oxopropyl)-4-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

4/8/2003


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-50-5 CAPLUS  
CN Piperazine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 434949-53-8 CAPLUS  
CN Piperazine, 1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-(1-oxobutyl)- (9CI) (CA INDEX NAME)




RN 434949-56-1 CAPLUS  
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



PAGE 1-A


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-68-1 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[(4-(4-hydroxy-1-piperidinyl)sulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

PAGE 2-A


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-71-0 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-(4-hydroxy-1-piperidinyl)sulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)



RN 434949-74-3 CAPLUS  
CN Piperazine, 1-[(4-(4-hydroxy-1-piperidinyl)sulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)




RN 434949-77-6 CAPLUS  
CN Piperidine, 1-[4-[(4-(4-hydroxy-1-piperidinyl)sulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 434949-79-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-(4-methyl-1-piperazinyl)sulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-81-2 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-(4-acetyl-1-piperazinyl)carbonyl)phenyl]amino]-4-pyrimidinyl]phenyl]sulfonyl)- (9CI) (CA INDEX NAME)



RN 434949-83-4 CAPLUS  
CN 4-Piperidinocarboxamide, 1-[(4-[(4-acetyl-1-piperazinyl)carbonyl]phenyl)amino]-4-pyrimidinyl]phenyl]sulfonyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 434949-85-6 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)




RN 434949-87-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[(4-(1-pyrrolidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-91-4 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-(1-pyrrolidinyl)-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-94-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(hexahydro-1H-azepin-1-yl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-95-8 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434949-96-9 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-97-0 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(3-methyl-1-piperidinyl)sulfonyl]phenyl]-2-pyrimidinylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434949-98-1 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-[(3-hydroxy-1-piperidinyl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434949-99-2 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-(1-piperazinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-03-5 CAPLUS  
CN Piperazine, 1-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-04-6 CAPLUS  
CN Piperazine, 1-[4-[(4-(1-pyrrolidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-05-7 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 434950-06-8 CAPLUS  
CN 1-Piperazinepropanamine, N,N-dimethyl-4-[(4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-07-9 CAPLUS  
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[(4-(1-piperidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 434950-08-0 CAPLUS  
CN Piperazine, 3,5-dimethyl-1-[4-[(4-(1-pyrrolidinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-09-1 CAPLUS

CN Piperazine, 1-(2-ethoxyethyl)-4-[(4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434950-10-4 CAPLUS


CN 1-Piperazinepropanamine, N,N-dimethyl-4-[(4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 434950-13-7 CAPLUS


CN Piperazine, 3,5-dimethyl-1-[4-[(4-(4-morpholinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 434950-14-8 CAPLUS

CN Piperazine, 1-(2-ethoxyethyl)-4-[(4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434950-15-9 CAPLUS


CN 1-Piperazineethanamine, N,N-dimethyl-4-[(4-[4-(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434950-33-1 CAPLUS


CN 1-Piperazinepropanamine, N,N-dimethyl-4-[(4-[4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-11-5 CAPLUS

CN 1-Piperazineethanamine, N,N-dimethyl-4-[(4-[4-(1-pyrrolidinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)




RN 434950-12-6 CAPLUS

CN 1-Piperazineethanamine, N,N-dimethyl-4-[(4-[4-(1-piperidinylsulfonyl)phenyl]-2-pyrimidinyl)amino]benzoyl- (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-34-2 CAPLUS


CN 4-Piperidinol, 1-[4-[(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)



RN 434950-35-3 CAPLUS


CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[(4-(4-pyridinylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 2-A




RN 434950-36-4 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)



RN 434950-37-5 CAPLUS  
CN 1-Piperazineacetamide,  
N-(1-methylethyl)-4-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)



RN 434950-38-6 CAPLUS  
CN Piperazine, 1-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 434950-39-7 CAPLUS

CN Piperazine, 3-methyl-1-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 434950-40-0 CAPLUS  
CN Piperidine, 4-(1-pyrrolidinyl)-1-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-41-1 CAPLUS  
CN 4-Piperidinol, 1-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-42-2 CAPLUS  
CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)carbonyl]-4-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




RN 434950-43-3 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)




RN 434950-44-4 CAPLUS  
CN Piperazine, 1-[4-[(4-pyridinylsulfonyl)phenyl]-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-45-5 CAPLUS  
CN Piperazine, 1-(2-ethoxyethyl)-4-[4-[(4-[(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl - (9CI) (CA INDEX NAME)



RN 434950-46-6 CAPLUS  
CN Piperazine, 1-[4-[(4-[(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl]-4-[(tetrahydro-2-furanyl)methyl] - (9CI) (CA INDEX NAME)




RN 434950-47-7 CAPLUS  
CN Piperazine, 1-acetyl-4-[4-[(4-[(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl] - (9CI) (CA INDEX NAME)




RN 434950-48-8 CAPLUS  
CN Piperazine, 1-(2-furanylcarbonyl)-4-[4-[(4-[(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino]benzoyl] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 434950-49-9 CAPLUS  
CN Piperazine, 1-methyl-1-4-[(4-[(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino)benzoyl]- (9CI) (CA INDEX NAME)




RN 434950-50-2 CAPLUS  
CN Piperazine, 1-4-[(4-[(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino)benzoyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 434950-51-3 CAPLUS  
CN 1-Piperazinepropanamine,  
N,N-dimethyl-4-[(4-[(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino)benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 434950-52-4 CAPLUS  
CN Benzamide, N-(4-hydroxycyclohexyl)-4-[(4-[(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)



RN 434950-53-5 CAPLUS  
CN Benzamide, N,N-dimethyl-4-[(4-[(4-(phenylsulfonyl)phenyl)-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)




IT 434950-65-9P 434950-68-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of anilinopyrimidines as JNK pathway inhibitors)  
RN 434950-65-9 CAPLUS  
CN Benzoic acid,  
4-[(4-[(4-morpholinylsulfonyl)phenyl]-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)




RN 434950-68-2 CAPLUS

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
CN Benzoic acid, 4-[(4-[(tetrahydro-2H-pyran-4-yl)sulfonyl]phenyl)-2-pyrimidinyl]amino)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 200231429 CAPLUS  
DOCUMENT NUMBER: 136:102394  
TITLE: Aryl phenylheterocyclic sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents  
INVENTOR(S): Wang, Gary T.; Wang, Sheldon; Gentles, Robert  
PATENT ASSIGNEE(S): Abbott Lab., USA  
SOURCE: PCT Int. Appl., 135 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002539	A1	20020110	WO 2001-US20128	20010622
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TW, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, EP 1294704	A1	20030326	EP 2001-946705	20010622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: US 2000-606717			US 2000-606717	A 20000629
OTHER SOURCE(S): GI			WO 2001-US20128	W 20010622




AB Title compds. were prep'd. for treating inflammatory and immune diseases, such as arthritis, asthma, reperfusion injury, inflammatory bowel disease etc. The products had IC<sub>50</sub> <20 mM for inhibition of ICAM-1 binding to LPA-1. 2-Me2CH<sub>2</sub>SH was etherified with 4,3-F(FC)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>, followed by bromination, and reaction with 1-carbamoylpiperidine to give the sulfide I.

IT 388118-57-8P 388118-58-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of aryl phenylheterocyclic sulfides as cell adhesion-inhibiting, anti-inflammatory and immunosuppressive agents)  
RN 388118-57-8 CAPLUS


4/8/2003

Habte

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 CN 4-(1H)-Pyrimidinone, 6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 388118-58-9 CAPLUS  
 CN Pyrimidine, 4-chloro-6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



IT 388117-63-3P 388117-64-4P 388117-65-5P  
 388117-66-6P 388117-67-7P 388117-68-8P  
 388117-69-9P 388117-70-2P 388117-71-3P  
 388117-72-4P 388117-73-5P 388117-74-6P  
 388117-75-7P 388117-76-8P 388117-77-9P  
 388117-78-0P 388117-79-1P 388117-80-4P  
 388117-81-5P 388117-82-6P 388117-83-7P  
 388117-84-8P 388117-85-9P 388117-86-0P  
 388117-87-1P


RL: SWN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of aryl phenylheterocyclyl sulfides as cell adhesion-inhibiting antiinflammatory and immunosuppressive agents)

RN 388117-63-3 CAPLUS  
 CN Morpholine, 4-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-64-4 CAPLUS  
 CN 4-Piperidinol, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)  
 (trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 388117-65-5 CAPLUS  
 CN Morpholine, 2,6-dimethyl-4-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-66-6 CAPLUS  
 CN 3-Piperidinecarboxamide, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 388117-67-7 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-68-8 CAPLUS  
 CN Acetamide, N-ethyl-N-[1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)




RN 388117-69-9 CAPLUS  
 CN 3-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-70-2 CAPLUS  
 CN 4-Piperidinecarboxylic acid, 1-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-71-3 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 388117-72-4 CAPLUS  
 CN 1-Piperazineacetic acid, 4-[6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 388117-73-5 CAPLUS  
 CN 4-Pyrimidinamine, N-[3-(1H-imidazol-1-yl)propyl]-6-[4-[(2-(1-methylethyl)phenyl]thio]-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




Absolute stereochemistry.




Absolute stereochemistry.

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 388117-85-9 CAPLUS  
 CN Carbamic acid, [1-[6-[(4-[(2-(1-methylethyl)phenyl)thio]-3-(trifluoromethyl)phenyl)-4-pyrimidinyl]-3-pyrrolidinyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 388117-86-0 CAPLUS  
 CN 4-Pyrimidinamine, N-methyl-N-(1-methylethyl)-6-((4-((2-(1-methylethyl)phenyl)thio)-3-(trifluoromethyl)phenyl)thio)-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 388117-87-1 CAPLUS  
 CN 4-Pyrimidinamine, N-ethyl-N-methyl-6-((2-(1-methylethyl)phenyl)thio)-3-(trifluoromethyl)phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992-612432 CAPLUS

DOCUMENT NUMBER: 117-212432

TITLE: Studies on cerebral protective agents. I. Novel 4-arylpymidine derivatives with anti-anoxic and anti-lipid peroxidation activities

AUTHOR(S): Kuno, Atsushi; Sugiyama, Yoshiie; Katsuma, Kiyotaka; Hamanishi, Toshiharu; Takasugi, Hisashi


CORPORATE SOURCE: New Drug Res. Lab., Fujisawa Pharm. Co., Ltd., Osaka, 532, Japan

SOURCE: Chemical &amp; Pharmaceutical Bulletin (1992), 40(6), 1452-61

DOCUMENT TYPE: CODEN: CPBTAL; ISSN: 0009-2363

LANGUAGE: Journal

GI English



AB Novel 4-arylpymidine derivs. were synthesized by the oxdn. of 4-aryl-1,4-dihydropyrimidines, and their effects on anti-anoxic (AA) activity in mice and anti-lipid peroxidn. (ALP) activity in rat brain mitochondria were investigated. Among these compds., Et 6-methyl-2-phenyl-4-(4-pyridyl)-5-pyrimidinecarboxylate (I, R = 4-pyridyl)

has AA activity (10 mg/kg, i.p.) and Et 6-methyl-4-(3-nitrophenyl)-2-phenyl-5-pyrimidinecarboxylate (I, R = 3-O<sub>2</sub>NCH<sub>2</sub>H<sub>4</sub>) has ALP activity (73% inhibition at 10-5 g/ml). The latter compd. (100 mg/kg, i.p.) was also effective on arachidonate-induced cerebral edema in rats with comparable potency to that of Vitamin E.


IT 103293-67-0

RL: SPN (Synthetic preparation); PREP (Preparation)

(prep.), anti-anoxic and antilipid peroxidn. activities of

RN 103293-67-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(2-[(4-chlorophenyl)thio]phenyl)-6-methyl-2-phenyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1986-572492 CAPLUS  
 DOCUMENT NUMBER: 105-172492  
 TITLE: Pyrimidine derivatives  
 INVENTOR(S): Takaya, Takao; Takasugi, Hisashi; Kuno, Atsushi;  
 Sugiyama, Yoshiie  
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan  
 SOURCE: Eur. Pat. Appl., 192 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 169712	A2	19860129	EP 1985-305143	19850718
EP 169712	A3	19861203		
EP 169712	B1	19901212		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4698340	A	19871006	US 1985-753912	19850711
ZA 8505369	A	19860625	ZA 1985-5369	19850716
FI 8502796	A	19860120	FI 1985-2796	19850717
NO 8502869	A	19860120	NO 1985-2869	19850718
DK 8503279	A	19860120	DK 1985-3279	19850718
ES 545347	A1	19861016	ES 1985-545347	19850718
AT 59034	E	19901215	AT 1985-305143	19850718
AU 8545202	A1	19860123	AU 1985-45202	19850719
JP 61040272	A2	19860226	JP 1985-160784	19850719
JP 06049688	B4	19940629		
US 4727073	A	19880223	US 1985-779043	19850923
ZA 8507359	A	19860528	ZA 1985-7359	19850924
FI 8503698	A	19860402	FI 1985-3698	19850926
EP 177287	A2	19860409	EP 1985-306880	19850927
EP 177287	A3	19861126		
EP 177287	B1	19901205		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 58697	E	19901215	AT 1985-306880	19850927
DK 8504436	A	19860402	DK 1985-4436	19850930
NO 8503853	A	19860402	NO 1985-3853	19850930
ES 547419	A1	19870316	ES 1985-547419	19850930
AU 8548143	A1	19860410	AU 1985-48143	19851001
JP 61087669	A2	19860506	JP 1985-219010	19851001
PRIORITY APPLN. INFO.:				
GB 1984-18380			19840719	
GB 1984-24711			19841001	
GB 1985-9623			19850415	
GB 1985-9633			19850415	
EP 1985-305143			19850718	
EP 1985-306880			19850927	

GI

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS (Continued)



AB Pyrimidines I (R = substituted aryl; R1 = CO<sub>2</sub>H, esterified CO<sub>2</sub>H, alkanoyl,  
 etc.; R2 = H, aryl, alkyl, etc.; R3 = alkyl, aryl) were prep'd., and they  
 showed their usefulness in the treatment of cerebrovascular diseases.  
 Dihydropyrimidine deriv. II was heated with MnO<sub>2</sub> to give I (R =  
 4-pyridyl,  
 R1 = CO<sub>2</sub>Et, R2 = Me, R3 = Ph). II was prep'd. from an .alpha.-  
 (arylmethylene)acetooacetate ester and an amide.  
 IT 103293-67-0  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, for treatment of cerebrovascular disease)  
 RN 103293-67-0 CAPLUS  
 CN 5-Pyrimidinecarboxylic acid,  
 4-[2-[(4-chlorophenyl)thiophenyl]-6-methyl-2-  
 phenyl-, ethyl ester (9CI) (CA INDEX NAME)



09/888840

Page 27

=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	28.05	176.41
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.91	-3.91

STN INTERNATIONAL LOGOFF AT 17:34:56 ON 10 APR 2003